Research Analysts Set Expectations for ETON Q2 Earnings

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) – Research analysts at HC Wainwright lowered their Q2 2025 earnings estimates for Eton Pharmaceuticals in a research report issued to clients and investors on Wednesday, March 19th. HC Wainwright analyst S. Ramakanth now anticipates that the company will post earnings per share of $0.08 for the quarter, down from their prior forecast of $0.17. HC Wainwright has a “Buy” rating and a $33.00 price objective on the stock. The consensus estimate for Eton Pharmaceuticals’ current full-year earnings is ($0.14) per share. HC Wainwright also issued estimates for Eton Pharmaceuticals’ Q3 2025 earnings at $0.11 EPS, Q4 2025 earnings at $0.18 EPS, FY2025 earnings at $0.42 EPS, FY2026 earnings at $1.57 EPS, FY2027 earnings at $1.85 EPS, FY2028 earnings at $2.87 EPS and FY2029 earnings at $3.74 EPS.

A number of other equities analysts have also commented on the stock. Craig Hallum lifted their price target on shares of Eton Pharmaceuticals from $23.00 to $26.00 and gave the stock a “buy” rating in a report on Wednesday. B. Riley reiterated a “buy” rating and set a $24.00 price target (up previously from $21.00) on shares of Eton Pharmaceuticals in a report on Wednesday.

Eton Pharmaceuticals Stock Performance

Shares of NASDAQ:ETON opened at $14.22 on Friday. The firm has a market cap of $370.45 million, a PE ratio of -64.64 and a beta of 1.37. The firm’s fifty day moving average is $15.58 and its 200-day moving average is $11.54. Eton Pharmaceuticals has a 52 week low of $3.03 and a 52 week high of $18.41.

Eton Pharmaceuticals (NASDAQ:ETON) last issued its quarterly earnings results on Tuesday, March 18th. The company reported ($0.02) EPS for the quarter, hitting analysts’ consensus estimates of ($0.02). The company had revenue of $11.65 million for the quarter, compared to analyst estimates of $10.53 million. Eton Pharmaceuticals had a negative net margin of 15.81% and a negative return on equity of 36.29%.

Hedge Funds Weigh In On Eton Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of ETON. Mink Brook Asset Management LLC acquired a new position in Eton Pharmaceuticals in the fourth quarter valued at $6,071,000. Cannell Capital LLC acquired a new position in Eton Pharmaceuticals in the fourth quarter valued at $5,079,000. Wasatch Advisors LP acquired a new position in Eton Pharmaceuticals in the third quarter valued at $1,431,000. Connor Clark & Lunn Investment Management Ltd. lifted its holdings in Eton Pharmaceuticals by 230.5% in the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 214,878 shares of the company’s stock valued at $2,862,000 after buying an additional 149,864 shares during the period. Finally, Millennium Management LLC acquired a new position in Eton Pharmaceuticals in the fourth quarter valued at $1,850,000. Institutional investors and hedge funds own 27.86% of the company’s stock.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.